Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial

Yudkin, Patricia; Munafò, Marcus R.; Hey, Kate; Roberts, S. J.; Welch, Sarah; Johnstone, Elaine; Murphy, Michael; Griffiths, Sian

doi:10.1136/bmj.38050.674826

Cited by 57 publications

(41 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is quite conventional to analyze outcomes at the end of treatment and more distant posttreatment follow-ups separately, as seen in other pharmacogenetic trials Lerman, Shields et al, 2002;Swan et al, 2005;Yudkin et al, 2004). This is the case because after cessation of treatment, genes would not, by definition be interacting with treatment per se, but rather would be interacting with persistent neuropsychological adaptations resulting from treatment.…”

Section: Discussionmentioning

confidence: 99%

Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation

David

Brown

Papandonatos

et al. 2007

CNTR

View full text Add to dashboard Cite

This randomized, double-blinded, placebo-controlled trial examined genetic influences on treatment response to sustained-release bupropion for smoking cessation. Smokers of European ancestry (N = 291), who were randomized to receive bupropion or placebo (12 weeks) plus counseling, were genotyped for the dopamine D2 receptor (DRD2-Taq1A), dopamine transporter (SLC6A3 3' VNTR), and cytochrome P450 2B6 (CYP2B6 1459 CT) polymorphisms. Main outcome measures were cotinine-verified point prevalence of abstinence at end of treatment and at 2-, 6-, and 12-month follow-ups post quit date. Using generalized estimating equations, we found that bupropion, compared with placebo, was associated with significantly greater odds of abstinence at all time points (all p values<.01). We found a significant DRD2 x bupropion interaction (B = 1.49, SE = 0.59, p = .012) [corrected] and a three-way DRD2 x bupropion x craving interaction on 6-month smoking cessation outcomes (B = -0.45, SE = 0.22, p = .038), such that smokers with the A2/A2 genotype demonstrated the greatest craving reduction and the highest abstinence rates with bupropion. Furthermore, there was a significant DRD2 x CYP2B6 interaction (B = 1.43, SE = 0.56, p = .01), such that individuals with the DRD2-Taq1 A2/A2 genotype demonstrated a higher odds of abstinence only if they possessed the CYP2B6 1459 T/T or C/T genotype. Because the sample size of this study was modest for pharmacogenetic investigations, the results should be interpreted with caution. Although these results require replication, the data suggest preliminarily that the DRD2-Taq1A polymorphism may influence treatment response to bupropion for smoking cessation and, further, that exploration of gene x gene and gene x craving interactions in future, larger studies may provide mechanistic insights into the complex pharmacodynamics of bupropion.

show abstract

Section: Discussionmentioning

confidence: 99%

Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation

David

Brown

Papandonatos

et al. 2007

CNTR

View full text Add to dashboard Cite

show abstract

“…There is little evidence that ethnicity predicts differences in pharmacological responsiveness because it cannot be given a precise biological definition (Nuffield Council on Bioethics 2003). In contrast, a genetic basis for differences in individual drug responses has been shown between men and women, such as in their responsiveness to nicotine patches (Yudkin et al 2004). Given the significant heterogeneity of the Aboriginal population within Australia, it is not possible to make any generalisation about an ethnographic basis for differences in drug responses .…”

Section: The Research Focus Is Holistic and Not Just Biomedicalmentioning

confidence: 99%

‘We are Not Just Participants—We are in Charge’: The NACCHO Ear Trial and the Process for Aboriginal Community-controlled Health Research

Couzos¹,

Lea²,

Murray³

et al. 2005

Ethnicity & Health

108

View full text Add to dashboard Cite

The 22 methodological elements which defined the community-controlled design of the ear trial may assist community groups, external research bodies and funding agencies to improve the acceptability, quality and scope of research involving Indigenous peoples. Aboriginal community-controlled organisations are well placed to lead research, which can be interventional and of a high scientific standard without compromising the values and principles of those being researched. With over 120 Aboriginal community-controlled health services (ACCHSs) across Australia, the potential exists for these services to engage in multi-centre research to realise solutions to health problems faced by Indigenous Australians.

show abstract

“…Additional details about both trials are reported in the debut clinical trial outcome papers (Aveyard et al, 2007;GPRG, 1993GPRG, , 1994b and subsequent pharmacogenetic investigation papers (David et al, 2002;Johnstone, Clark, Griffiths, Murphy, & Walton, 2002;Johnstone, Yudkin, Griffiths, et al, 2004;McKinney et al, 2000;Munafò, Zetteler, & Clark, 2007;Yudkin et al, 2004).…”

Section: Methods Of Patch II and Pip Trialsmentioning

confidence: 99%

“…Blood sample receipt and processing, DNA extraction, assays, primers, PCR, and other genotyping procedures are described in detail elsewhere David et al, 2002;Johnstone et al, 2002Johnstone, Yudkin, Griffiths, et al, 2004 ;Huang, Payne, Ma, & Li, 2008;Lerman et al, 1997;McKinney et al, 2000;Yudkin et al, 2004). The full list of polymorphisms genotyped is in Supplementary Table 1 and other genotyping details are available upon request.…”

Section: Dna Extraction and Genotypingmentioning

confidence: 99%

Pharmacogenetics of Smoking Cessation in General Practice: Results From the Patch II and Patch in Practice Trials

David

Johnstone

Churchman

et al. 2011

Nicotine &Amp; Tobacco Research

View full text Add to dashboard Cite

of pharmacogenetic and genomic investigations of smoking cessation and its translation to primary care. IntroductionTobacco smoking remains a leading cause of preventable death internationally, with worldwide smoking-attributable deaths approaching 10 million annually by 2030(Peto et al., 1996. Most smokers in developed countries present in primary care settings, providing an opportunity for general practitioners (GPs) to treat patients with nicotine dependence, but even with major advances in pharmacotherapy in recent decades, there remains room for improvement (Fiore et al., 2000(Fiore et al., , 2008. In a coordinated effort to advance the state of the science, a transdisciplinary research team, the General Practice Research Group (GPRG), embarked on an initiative to explore genetic moderation of drug response for smoking cessation. ObjectivesA formative review, published at the outset of the present project, described its conceptual framework (Walton, Johnstone, Munafò, Neville, & Griffiths, 2001). The objectives of this summative article are to (a) provide an historical narrative of the rationale, developmental, and deductive process that guided the GPRG's pharmacogenetic smoking cessation research initiative; (b) present new and extant pharmacogenetic data in full; and (c) synthesize results and apply theoretical and practical lessons learned toward proposed best-practice research models to guide future translation to clinical practice. AbstractIntroduction: Cigarette smoking remains the leading cause of preventable death worldwide. However, the efficacy of available first-line therapies remains low, particularly in primary care practice where most smokers seek and receive treatment. These observations reinforce the notion that 'one size fits all' smoking cessation therapies may not be optimal. Therefore, a translational research effort was launched by the Imperial Cancer Research Fund (later Cancer Research UK) General Practice Research Group, who led a decade-long research enterprise that examined the influence of pharmacological hypothesis-driven research into genetic influences on drug response for smoking cessation with transdermal nicotine replacement therapy in general practice.Methods: New and previously published smoking cessation genetic association results of 30 candidate gene polymorphisms genotyped for participants in two transdermal nicotine replacement clinical trials based in UK general practices, which employed an intention to analyze approach.Results: By this high bar, one of the polymorphisms (COMT rs4680) was robust to correction for multiple comparisons. Moreover, future research directions are outlined; and lessons learned as well as best-practice models for designing, analyzing, and translating results into clinical practice are proposed. Conclusions:The results and lessons learned from this general practice-based pharmacogenetic research programme provide transportable insights at the transition to the second generation

show abstract

Effectiveness of nicotine patches in relation to genotype in women versus men: randomised controlled trial

Cited by 57 publications

References 4 publications

Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation

Pharmacogenetic clinical trial of sustained-release bupropion for smoking cessation

‘We are Not Just Participants—We are in Charge’: The NACCHO Ear Trial and the Process for Aboriginal Community-controlled Health Research

Pharmacogenetics of Smoking Cessation in General Practice: Results From the Patch II and Patch in Practice Trials

Contact Info

Product

Resources

About